Inquire Before Buying
Speak to an Analyst 
Request Brochure 
Request CustomizationIMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
Read More
Idiopathic Pulmonary Fibrosis Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027
Report Format: PDF+Excel | Report ID: SR112023A2507
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Idiopathic Pulmonary Fibrosis Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Class
6.1 MAPK Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Tyrosine Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Autotaxin Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by End User
7.1 Hospitals
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Long-term Care Facilities
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Others
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Region
8.1 North America
8.1.1 United States
8.1.1.1 Market Trends
8.1.1.2 Market Forecast
8.1.2 Canada
8.1.2.1 Market Trends
8.1.2.2 Market Forecast
8.2 Asia Pacific
8.2.1 China
8.2.1.1 Market Trends
8.2.1.2 Market Forecast
8.2.2 Japan
8.2.2.1 Market Trends
8.2.2.2 Market Forecast
8.2.3 India
8.2.3.1 Market Trends
8.2.3.2 Market Forecast
8.2.4 South Korea
8.2.4.1 Market Trends
8.2.4.2 Market Forecast
8.2.5 Australia
8.2.5.1 Market Trends
8.2.5.2 Market Forecast
8.2.6 Indonesia
8.2.6.1 Market Trends
8.2.6.2 Market Forecast
8.2.7 Others
8.2.7.1 Market Trends
8.2.7.2 Market Forecast
8.3 Europe
8.3.1 Germany
8.3.1.1 Market Trends
8.3.1.2 Market Forecast
8.3.2 France
8.3.2.1 Market Trends
8.3.2.2 Market Forecast
8.3.3 United Kingdom
8.3.3.1 Market Trends
8.3.3.2 Market Forecast
8.3.4 Italy
8.3.4.1 Market Trends
8.3.4.2 Market Forecast
8.3.5 Spain
8.3.5.1 Market Trends
8.3.5.2 Market Forecast
8.3.6 Russia
8.3.6.1 Market Trends
8.3.6.2 Market Forecast
8.3.7 Others
8.3.7.1 Market Trends
8.3.7.2 Market Forecast
8.4 Latin America
8.4.1 Brazil
8.4.1.1 Market Trends
8.4.1.2 Market Forecast
8.4.2 Mexico
8.4.2.1 Market Trends
8.4.2.2 Market Forecast
8.4.3 Others
8.4.3.1 Market Trends
8.4.3.2 Market Forecast
8.5 Middle East and Africa
8.5.1 Market Trends
8.5.2 Market Breakup by Country
8.5.3 Market Forecast
9 SWOT Analysis
9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
13.3.1 AdAlta Pty Ltd.
13.3.1.1 Company Overview
13.3.1.2 Product Portfolio
13.3.1.3 Financials
13.3.2 Angion Biomedica Corp.
13.3.2.1 Company Overview
13.3.2.2 Product Portfolio
13.3.3 Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG)
13.3.3.1 Company Overview
13.3.3.2 Product Portfolio
13.3.3.3 Financials
13.3.4 Bristol-Myers Squibb Company
13.3.4.1 Company Overview
13.3.4.2 Product Portfolio
13.3.4.3 Financials
13.3.4.4 SWOT Analysis
13.3.5 Cipla Inc.
13.3.5.1 Company Overview
13.3.5.2 Product Portfolio
13.3.5.3 Financials
13.3.5.4 SWOT Analysis
13.3.6 F. Hoffmann-La Roche AG (Roche Holding AG)
13.3.6.1 Company Overview
13.3.6.2 Product Portfolio
13.3.6.3 SWOT Analysis
13.3.7 Fibrogen Inc.
13.3.7.1 Company Overview
13.3.7.2 Product Portfolio
13.3.7.3 Financials
13.3.8 Galapagos NV
13.3.8.1 Company Overview
13.3.8.2 Product Portfolio
13.3.8.3 Financials
13.3.9 Liminal BioSciences Inc.
13.3.9.1 Company Overview
13.3.9.2 Product Portfolio
13.3.9.3 Financials
13.3.10 Medicinova Inc.
13.3.10.1 Company Overview
13.3.10.2 Product Portfolio
13.3.10.3 Financials
13.3.10.4 SWOT Analysis
13.3.11 Merck & Co. Inc.
13.3.11.1 Company Overview
13.3.11.2 Product Portfolio
13.3.11.3 Financials
13.3.11.4 SWOT Analysis
13.3.12 Novartis AG
13.3.12.1 Company Overview
13.3.12.2 Product Portfolio
13.3.12.3 Financials
13.3.12.4 SWOT Analysis
13.3.13 Vectura Group Plc
13.3.13.1 Company Overview
13.3.13.2 Product Portfolio
13.3.13.3 Financials
13.3.13.4 SWOT Analysis
List of Figures
Figure 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Major Drivers and Challenges
Figure 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016-2021
Figure 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Drug Class (in %), 2021
Figure 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by End User (in %), 2021
Figure 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Breakup by Region (in %), 2021
Figure 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 7: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 8: Global: Idiopathic Pulmonary Fibrosis Treatment (MAPK Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 9: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Idiopathic Pulmonary Fibrosis Treatment (Tyrosine Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Idiopathic Pulmonary Fibrosis Treatment (Autotaxin Inhibitors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Idiopathic Pulmonary Fibrosis Treatment (Hospitals) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Idiopathic Pulmonary Fibrosis Treatment (Long-term Care Facilities) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Idiopathic Pulmonary Fibrosis Treatment (Other End Users) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: North America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: North America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: United States: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: United States: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Canada: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Canada: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Asia Pacific: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: China: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: China: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Japan: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Japan: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: India: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: India: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: South Korea: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: Australia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: Australia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: Indonesia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Europe: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Europe: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: Germany: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: Germany: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: France: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: France: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: United Kingdom: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: Italy: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: Italy: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Spain: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Spain: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Russia: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Russia: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Latin America: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Brazil: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: Mexico: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: Others: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: Others: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Middle East and Africa: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: SWOT Analysis
Figure 68: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Value Chain Analysis
Figure 69: Global: Idiopathic Pulmonary Fibrosis Treatment Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Drug Class (in Million US$), 2022-2027
Table 3: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 4: Global: Idiopathic Pulmonary Fibrosis Treatment Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 5: Global: Idiopathic Pulmonary Fibrosis Treatment Market Structure
Table 6: Global: Idiopathic Pulmonary Fibrosis Treatment Market: Key Players
Select Licence Type
Benefits of Customization
Personalize This Research
Triangulate with your Data
Get Data as per your Format and Definition
Gain a Deeper Dive into a Specific Application, Geography, Customer or Competitor
Any level of Personalization
Get in Touch With Us
UNITED STATES
Phone: +1-631-791-1145
INDIA
Phone: +91-120-433-0800
UNITED KINGDOM
Phone: +44-753-713-2163
Email: sales@imarcgroup.com
Clients Testimonial
It was indeed a great experience to work with IMARC on the assignment on Aqua market. The team had done a fantastic job in terms of what was expected, what was assured and what was the result… the report gave us many insights and market know how which allowed us to work on our strength and define exact strategies…
Read More
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
Read More
Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.
Read More.webp)
We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.
Read More
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
Read More
The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.
Read More
My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.
Read More
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
Read More.webp){kind=logo}
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.
Read More
IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.
Read More
